References (Continued)

31. Hoskin PJ, Bownes P, Summers A. The influence of applicator angle on dosimetry in vaginal vault brachytherapy. Br J Radiol. 2002;75(891):234–237.


Continue Reading

32. Sabater S, Arenas M, Berenguer R, et al. Dosimetric analysis of rectal filling on rectal doses during vaginal cuff brachytherapy. Brachytherapy. 2015;14(4):458–463.

33. Hung J, Shen S, De Los Santos JF, Kim RY. Image-based 3D treatment planning for vaginal cylinder brachytherapy: dosimetric effects of bladder filling on organs at risk. Int J Radiat Oncol Biol Phys. 2012;83(3):980–985.

34. Harkenrider MM, Block AM, Alektiar KM, et al. American Brachytherapy Task Group Report: adjuvant vaginal brachytherapy for early-stage endometrial cancer: a comprehensive review. Brachytherapy. 2017;16(1):95–108.

35. Meyer LA, Bohlke K, Powell MA, et al. Postoperative radiation therapy for endometrial cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Evidence-Based Guideline. J Clin Oncol. 2015;33(26):2908–2913.

36. Sorbe B, Nordstrom B, Maenpaa J, et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer. 2009;19(5):873–878.

37. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404–1411.

38. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92(3):744–751.

39. Kong A, Johnson N, Kitchener HC, Lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer. Cochrane Database Syst Rev. 2012;(4):CD003916.

40. Sorbe B, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma – a prospective randomized study. Int J Radiat Oncol Biol Phys. 2012;82(3):1249–1255.

41. Wright JD, Fiorelli J, Kansler AL, et al. Optimizing the management of stage II endometrial cancer: the role of radical hysterectomy and radiation. Am J Obstet Gynecol. 2009;200(4):419.e1–419.e7.

42. Rydzewski NR, Strohl AE, Donnelly ED, et al. Receipt of vaginal brachytherapy is associated with improved survival in women with stage I endometrioid adenocarcinoma of the uterus: a National Cancer Data Base study. Cancer. 2016;122(23):3724–3731.

43. Bingham B, Orton A, Boothe D, et al. Brachytherapy improves survival in stage III endometrial cancer with cervical involvement. Int J Radiat Oncol Biol Phys. 2017;97(5):1040–1050.

44. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816–823.

45. Onsrud M, Cvancarova M, Hellebust TP, Trope CG, Kristensen GB, Lindemann K. Long-term outcomes after pelvic radiation for early-stage endometrial cancer. J Clin Oncol. 2013;31(31):3951–3956.

46. Kim A, Schreiber D, Rineer J, Choi K, Rotman M. Impact of adjuvant external-beam radiation therapy in early-stage uterine papillary serous and clear cell carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e639–e644.

47. Nagar H, Yan W, Parashar B, et al. Adjuvant pelvic radiation therapy±vaginal brachytherapy in patients with high-risk stage I or stage II uterine papillary serous, clear cell, and high-grade endometrioid carcinoma. Am J Clin Oncol. 2016;39(4):335–339.

48. Crosby MA, Tward JD, Szabo A, Lee CM, Gaffney DK. Does brachytherapy improve survival in addition to external beam radiation therapy in patients with high risk stage I and II endometrial carcinoma? Am J Clin Oncol. 2010;33(4):364–369.

49. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(1):36–44.

50. Small W Jr, Du Bois A, Bhatnagar S, et al. Practice patterns of radiotherapy in endometrial cancer among member groups of the gynecologic cancer intergroup. Int J Gynecol Cancer. 2009;19(3):395–399.

51. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94(5):642–646.

52. Aalders J, Abeler V, Kolstad P, Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol. 1980;56(4):419–427.

53. Ly D, Rowley BD, Dodson MK, et al. Adjuvant radiation in early stage, unfavorable histology endometrial carcinoma is associated with improved local control and survival. Gynecol Oncol. 2014;133(2):250–255.

54. Susumu N, Sagae S, Udagawa Y, et al. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group Study. Gynecol Oncol. 2008;108(1):226–233.

55. Maggi R, Lissoni A, Spina F, et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer. 2006;95(3):266–271.

56. Townamchai K, Berkowitz R, Bhagwat M, et al. Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer. Gynecol Oncol. 2013;129(1):18–21.

57. Tetreault-Laflamme A, Nguyen-Huynh TV, Carrier JF, et al. Adjuvant chemotherapy and vaginal vault brachytherapy with or without pelvic radiotherapy for stage 1 papillary serous or clear cell endometrial cancer. Int J Gynecol Cancer. 2016;26(2):301–306.

58. Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi33–38.

59. Sorbe B, Straumits A, Karlsson L. Intravaginal high-dose-rate brachytherapy for stage I endometrial cancer: a randomized study of two dose-per-fraction levels. Int J Radiat Oncol Biol Phys. 2005;62(5):1385–1389.

60. Rovirosa A, Ascaso C, Arenas M, et al. Can we shorten the overall treatment time in postoperative brachytherapy of endometrial carcinoma? Comparison of two brachytherapy schedules. Radiother Oncol. 2015;116(1):143–148.

61. Rios I, Rovirosa A, Ascaso C, et al. Vaginal-cuff control and toxicity results of a daily HDR brachytherapy schedule in endometrial cancer patients. Clin Transl Oncol. 2016;18(9):925–930.

62. Rovirosa A, Ascaso C, Herreros A, et al. A new short daily brachytherapy schedule in postoperative endometrial carcinoma. Preliminary results. Brachytherapy. 2017;16(1):147–152.

63. Harkenrider MM, Grover S, Erickson BA, et al. Vaginal brachytherapy for postoperative endometrial cancer: 2014 Survey of the American Brachytherapy Society. Brachytherapy. 2016;15(1):23–29.

64. Cameron AL, Cornes P, Al-Booz H. Brachytherapy in endometrial cancer: quantification of air gaps around a vaginal cylinder. Brachytherapy. 2008;7(4):355–358.

65. Demanes DJ, Rege S, Rodriquez RR, Schutz KL, Altieri GA, Wong T. The use and advantages of a multichannel vaginal cylinder in high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 1999;44(1):211–219.

66. Kim RY, Pareek P, Duan J, Murshed H, Brezovich I. Postoperative intravaginal brachytherapy for endometrial cancer; dosimetric analysis of vaginal colpostats and cylinder applicators. Brachytherapy. 2002;1(3):138–144.

67. Vanneste BG, Meijnen P, Hammerstein CS, et al. Postoperative brachytherapy for endometrial cancer using a ring applicator. Brachytherapy. 2015;14(2):273–278.

68. El Khoury C, Dumas I, Tailleur A, Morice P, Haie-Meder C. Adjuvant brachytherapy for endometrial cancer: advantages of the vaginal mold technique. Brachytherapy. 2015;14(1):51–55.

69. Tuncel N, Garipagaoglu M, Kizildag AU, Andic F, Toy A. Optimisation techniques in vaginal cuff brachytherapy. Br J Radiol. 2009;82(983):936–940.

70. Nilsson S, Moutrie Z, Cheuk R, et al. A unique approach to high-dose-rate vaginal mold brachytherapy of gynecologic malignancies. Brachytherapy. 2015;14(2):267–272.

71. Arenas M, Sabater S, Sintas A, et al. Individualized 3D scanning and printing for non-melanoma skin cancer brachytherapy: a financial study for its integration into clinical workflow. J Contemp Brachytherapy. 2017;9(3):270–276.

72. Wiebe E, Easton H, Thomas G, Barbera L, D’Alimonte L, Ravi A. Customized vaginal vault brachytherapy with computed tomography imaging-derived applicator prototyping. Brachytherapy. 2015;14(3):380–384.

73. Miller DA, Richardson S, Grigsby PW. A new method of anatomically conformal vaginal cuff HDR brachytherapy. Gynecol Oncol. 2010;116(3):413–418.

74. Humphrey P, Cornes P, Al-Booz H. Vaginal vault brachytherapy in endometrial cancer: verifying target coverage with image-guided applicator placement. Br J Radiol. 2013;86(1023):20120428.

75. Richardson S, Palaniswaamy G, Grigsby PW. Dosimetric effects of air pockets around high-dose rate brachytherapy vaginal cylinders. Int J Radiat Oncol Biol Phys. 2010;78(1):276–279.

76. Hassouna A, Bahadur YA, Constantinescu C. Assessment of air pockets in high-dose-rate vaginal cuff brachytherapy using cylindrical applicators. J Contemp Brachytherapy. 2014;6(3):271–275.

77. Onal C, Guler OC, Dolek Y. The impact of air pockets around the vaginal cylinder on vaginal vault brachytherapy. Br J Radiol. 2015;88(1047):20140694.

78. Maxwell A, Thiruthaneeswaran N, Lowe G, Wills R, Sripali S, Hoskin PJ. The dosimetric impact of air in vaginal vault brachytherapy. Brachytherapy. 2016;15(6):832–838.

79. Patel S, Mehta KJ, Kuo HC, et al. Do changes in interfraction organ at risk volume and cylinder insertion geometry impact delivered dose in high-dose-rate vaginal cuff brachytherapy? Brachytherapy. 2016;15(2):185–190.

80. Owens KN, Patel HC, Yashar CM, Spanos WJ. Vaginal cuff brachytherapy for endometrial carcinoma: results of limiting vaginal coverage to one centimeter length. Brachytherapy. 2007;6:98–99.

81. Sorbe BG, Smeds AC. Postoperative vaginal irradiation with high dose rate afterloading technique in endometrial carcinoma stage I. Int J Radiat Oncol Biol Phys. 1990;18(2):305–314.

82. Kloetzer KH, Gunther R, Wendt T. Die Vaginalstumpf-Rezidivrate beim Endometriumkarzinom in Abhangigkeit des Zielvolumens der postoperativen HDR-Afterloading-Brachytherapie [The vaginal stump recurrence rate in endometrial carcinoma in relation to the target volume of postoperative HDR-afterloading brachytherapy]. Strahlenther Onkol. 1997;173(1):13–17.

83. Sabater S, Andres I, Jimenez-Jimenez E, et al. Rectal contrast increases rectal dose during vaginal cuff brachytherapy. Brachytherapy. 2016;15(1):35–39.

84. Sabater S, Sevillano M, Andres I, et al. Reduction of rectal doses by removal of gas in the rectum during vaginal cuff brachytherapy. Strahlenther Onkol. 2013;189:951–956.

85. Sabater S, Andres I, Gascon M, et al. Effect of rectal enemas on rectal dosimetric parameters during high-dose-rate vaginal cuff brachytherapy: a prospective trial. Strahlenther Onkol. 2016;192:248–253.

86. Andres I, Gutierrez-Perez M, Rodriguez-Vela MP, et al. The usefulness of fleet rectal enemas on high-dose-rate intracavitary cervical cancer brachytherapy. A prospective trial. J Contemp Brachytherapy. 2017;9(3):214–219.

87. Guler OC, Onal C, Acibuci I. Effects of bladder distension on dose distribution of vaginal vault brachytherapy in patients with endometrial cancer. J Contemp Brachytherapy. 2015;6(4):371–376.

88. Kobzda JD, Cikowska-Wozniak E, Michalska M, Makarewicz R. Three-dimensional dosimetry of the full and empty bladder in high dose rate vaginal cuff brachytherapy. Int J Gynecol Cancer. 2014;24(5):923–927.

89. Hoskin PJ, Vidler K. Vaginal vault brachytherapy: the effect of varying bladder volumes on normal tissue dosimetry. Br J Radiol. 2000;73(872):864–866.

90. Stewart AJ, Cormack RA, Lee H, et al. Prospective clinical trial of bladder filling and three-dimensional dosimetry in high-dose-rate vaginal cuff brachytherapy. Int J Radiat Oncol Biol Phys. 2008;72(3):843–848.

91. Russo JK, Armeson KE, Richardson S. Comparison of 2D and 3D imaging and treatment planning for postoperative vaginal apex high-dose rate brachytherapy for endometrial cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):e75–e80.

92. Kim H, Kim H, Houser C, Beriwal S. Is there any advantage to three-dimensional planning for vaginal cuff brachytherapy? Brachytherapy. 2012;11(5):398–401.

93. Choo JJ, Scudiere J, Bitterman P, Dickler A, Gown AM, Zusag TW. Vaginal lymphatic channel location and its implication for intracavitary brachytherapy radiation treatment. Brachytherapy. 2005;4(3):236–240.

94. Li S, Aref I, Walker E, Movsas B. Effects of prescription depth, cylinder size, treatment length, tip space, and curved end on doses in high-dose-rate vaginal brachytherapy. Int J Radiat Oncol Biol Phys. 2007;67(4):1268–1277.

95. Corso CD, Jarrio C, Nunnery EW, et al. Dosimetric and cost comparison of first fraction imaging versus fractional re-imaging on critical organ dose in vaginal cuff brachytherapy. Pract Radiat Oncol. 2013;3(4):256–262.

96. Zhou J, Prisciandaro J, Lee C, Schipper M, Eisbruch A, Jolly S. Single or multi-channel vaginal cuff high-dose-rate brachytherapy: is replanning necessary prior to each fraction? Pract Radiat Oncol. 2014;4(1):20–26.

97. Sabater S, Andres I, Sevillano M, Berenguer R, Machin-Hamalainen S, Arenas M. Dose accumulation during vaginal cuff brachytherapy based on rigid/deformable registration vs. single plan addition. Brachytherapy. 2014;13(4):343–351.

98. Symon Z, Menhel J, Alezra D, Pfeffer MR. Individual fraction optimization vs. first fraction optimization for multichannel applicator vaginal cuff high-dose-rate brachytherapy. Brachytherapy. 2006;5(4):211–215.

99. Haie-Meder C, Potter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiother Oncol. 2005;74(3):235–245.

100. Sabater S, Pastor-Juan Mdel R, Berenguer R, et al. Analysing the integration of MR images acquired in a non-radiotherapy treatment position into the radiotherapy workflow using deformable and rigid registration. Radiother Oncol. 2016;119(1):179–184.

101. Owrangi AM, Jolly S, Balter JM, et al. Clinical implementation of MR-guided vaginal cylinder brachytherapy. J Appl Clin Med Phys. 2015;16(6):490–500.

102. Chapman CH, Prisciandaro JI, Maturen KE, et al. MRI-based evaluation of the vaginal cuff in brachytherapy planning: are we missing the target? Int J Radiat Oncol Biol Phys. 2016;95(2):743–750.

103. Small W, Beriwal S, Demanes DJ, et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy. Brachytherapy. 2012;11(1):58–67.

104. Shih KK, Milgrom SA, Abu-Rustum NR, et al. Postoperative pelvic intensity-modulated radiotherapy in high risk endometrial cancer. Gynecol Oncol. 2013;128(3):535–539.

105. Ahamad A, D’Souza W, Salehpour M, et al. Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys. 2005;62(4):1117–1124.

106. Ma DJ, Michaletz-Lorenz M, Goddu SM, Grigsby PW. Magnitude of interfractional vaginal cuff movement: implications for external irradiation. Int J Radiat Oncol Biol Phys. 2012;82(4):1439–1444.

107. Jhingran A, Salehpour M, Sam M, Levy L, Eifel PJ. Vaginal motion and bladder and rectal volumes during pelvic intensity-modulated radiation therapy after hysterectomy. Int J Radiat Oncol Biol Phys. 2012;82(1):256–262.

108. Aydogan B, Mundt AJ, Smith BD, et al. A dosimetric analysis of intensity-modulated radiation therapy (IMRT) as an alternative to adjuvant high-dose-rate (HDR) brachytherapy in early endometrial cancer patients. Int J Radiat Oncol Biol Phys. 2006;65(1):266–273.

109. Low DA, Grigsby PW, Dempsey JF, et al. Applicator-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2002;52(5):1400–1406.

110. Cilla S, Macchia G, Sabatino D, et al. Applicator-guided volumetric-modulated arc therapy for low-risk endometrial cancer. Med Dosim. 2013;38(1):5–11.

111. Pedicini P, Caivano R, Fiorentino A, et al. Comparative dosimetric and radiobiological assessment among a nonstandard RapidArc, standard RapidArc, classical intensity-modulated radiotherapy, and 3D brachytherapy for the treatment of the vaginal vault in patients affected by gynecologic cancer. Med Dosim. 2012;37(4):347–352.

112. Pedicini P, Strigari L, Caivano R, et al. Local tumor control probability to evaluate an applicator-guided volumetric-modulated arc therapy solution as alternative of 3D brachytherapy for the treatment of the vaginal vault in patients affected by gynecological cancer. J Appl Clin Med Phys. 2013;14(2):4075.

113. Lanni TB Jr, Grills IS, Kestin LL, Robertson JM. Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J Clin Oncol. 2011;34(5):494–498.

114. Colombo N, Creutzberg C, Amant F, et al. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up. Int J Gynecol Cancer. 2016;26(1):2–30.

Source Cancer Management and Research.
Originally published August 9, 2017.